BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19019958)

  • 1. mRNA translation regulation by the Gly-Ala repeat of Epstein-Barr virus nuclear antigen 1.
    Apcher S; Komarova A; Daskalogianni C; Yin Y; Malbert-Colas L; Fåhraeus R
    J Virol; 2009 Feb; 83(3):1289-98. PubMed ID: 19019958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein Barr virus-encoded EBNA1 interference with MHC class I antigen presentation reveals a close correlation between mRNA translation initiation and antigen presentation.
    Apcher S; Daskalogianni C; Manoury B; Fåhraeus R
    PLoS Pathog; 2010 Oct; 6(10):e1001151. PubMed ID: 20976201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1.
    Yin Y; Manoury B; Fåhraeus R
    Science; 2003 Sep; 301(5638):1371-4. PubMed ID: 12958359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Messenger RNA sequence rather than protein sequence determines the level of self-synthesis and antigen presentation of the EBV-encoded antigen, EBNA1.
    Tellam JT; Lekieffre L; Zhong J; Lynn DJ; Khanna R
    PLoS Pathog; 2012 Dec; 8(12):e1003112. PubMed ID: 23300450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The nascent polypeptide-associated complex (NAC) controls translation initiation in cis by recruiting nucleolin to the encoding mRNA.
    Zheng AJL; Thermou A; Daskalogianni C; Malbert-Colas L; Karakostis K; Le Sénéchal R; Trang Dinh V; Tovar Fernandez MC; Apcher S; Chen S; Blondel M; Fahraeus R
    Nucleic Acids Res; 2022 Sep; 50(17):10110-10122. PubMed ID: 36107769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A yeast-based assay identifies drugs that interfere with immune evasion of the Epstein-Barr virus.
    Voisset C; Daskalogianni C; Contesse MA; Mazars A; Arbach H; Le Cann M; Soubigou F; Apcher S; Fåhraeus R; Blondel M
    Dis Model Mech; 2014 Apr; 7(4):435-44. PubMed ID: 24558096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1.
    Lee SP; Brooks JM; Al-Jarrah H; Thomas WA; Haigh TA; Taylor GS; Humme S; Schepers A; Hammerschmidt W; Yates JL; Rickinson AB; Blake NW
    J Exp Med; 2004 May; 199(10):1409-20. PubMed ID: 15148339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of proteasomal degradation by the gly-Ala repeat of Epstein-Barr virus is influenced by the length of the repeat and the strength of the degradation signal.
    Dantuma NP; Heessen S; Lindsten K; Jellne M; Masucci MG
    Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8381-5. PubMed ID: 10890896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeat sequence of Epstein-Barr virus-encoded nuclear antigen 1 protein interrupts proteasome substrate processing.
    Zhang M; Coffino P
    J Biol Chem; 2004 Mar; 279(10):8635-41. PubMed ID: 14688254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of antigen presentation by the glycine/alanine repeat domain is not conserved in simian homologues of Epstein-Barr virus nuclear antigen 1.
    Blake NW; Moghaddam A; Rao P; Kaur A; Glickman R; Cho YG; Marchini A; Haigh T; Johnson RP; Rickinson AB; Wang F
    J Virol; 1999 Sep; 73(9):7381-9. PubMed ID: 10438828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.
    Daskalogianni C; Pyndiah S; Apcher S; Mazars A; Manoury B; Ammari N; Nylander K; Voisset C; Blondel M; Fåhraeus R
    J Pathol; 2015 Jan; 235(2):334-41. PubMed ID: 25186125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type I arginine methyltransferases are intervention points to unveil the oncogenic Epstein-Barr virus to the immune system.
    Angrand G; Quillévéré A; Loaëc N; Dinh VT; Le Sénéchal R; Chennoufi R; Duchambon P; Keruzoré M; Martins RP; Teulade-Fichou MP; Fåhraeus R; Blondel M
    Nucleic Acids Res; 2022 Nov; 50(20):11799-11819. PubMed ID: 36350639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel cationic bis(acylhydrazones) as modulators of Epstein-Barr virus immune evasion acting through disruption of interaction between nucleolin and G-quadruplexes of EBNA1 mRNA.
    Reznichenko O; Quillévéré A; Martins RP; Loaëc N; Kang H; Lista MJ; Beauvineau C; González-García J; Guillot R; Voisset C; Daskalogianni C; Fåhraeus R; Teulade-Fichou MP; Blondel M; Granzhan A
    Eur J Med Chem; 2019 Sep; 178():13-29. PubMed ID: 31173968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus U leader exon contains an internal ribosome entry site.
    Isaksson A; Berggren M; Ricksten A
    Oncogene; 2003 Jan; 22(4):572-81. PubMed ID: 12555070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nucleolin directly mediates Epstein-Barr virus immune evasion through binding to G-quadruplexes of EBNA1 mRNA.
    Lista MJ; Martins RP; Billant O; Contesse MA; Findakly S; Pochard P; Daskalogianni C; Beauvineau C; Guetta C; Jamin C; Teulade-Fichou MP; Fåhraeus R; Voisset C; Blondel M
    Nat Commun; 2017 Jul; 8():16043. PubMed ID: 28685753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. cis-Inhibition of proteasomal degradation by viral repeats: impact of length and amino acid composition.
    Sharipo A; Imreh M; Leonchiks A; Brändén C; Masucci MG
    FEBS Lett; 2001 Jun; 499(1-2):137-42. PubMed ID: 11418128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nested open reading frame in the Epstein-Barr virus nuclear antigen-1 mRNA encodes a protein capable of inhibiting antigen presentation in cis.
    Ossevoort M; Zaldumbide A; te Velthuis AJ; Melchers M; Ressing ME; Wiertz EJ; Hoeben RC
    Mol Immunol; 2007 Jul; 44(14):3588-96. PubMed ID: 17449101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell specific internal translation efficiency of Epstein-Barr virus present in solid organ transplant patients.
    Isaksson A; Berggren M; Ekeland-Sjöberg K; Samuelsson T; Ricksten A
    J Med Virol; 2007 May; 79(5):573-81. PubMed ID: 17385682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Creation of immune 'stealth' genes for gene therapy through fusion with the Gly-Ala repeat of EBNA-1.
    Ossevoort M; Visser BM; van den Wollenberg DJ; van der Voort EI; Offringa R; Melief CJ; Toes RE; Hoeben RC
    Gene Ther; 2003 Nov; 10(24):2020-8. PubMed ID: 14566361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Gly-Ala repeat modulates the interaction of Epstein-Barr virus nuclear antigen-1 with cellular chromatin.
    Coppotelli G; Mughal N; Masucci MG
    Biochem Biophys Res Commun; 2013 Feb; 431(4):706-11. PubMed ID: 23348225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.